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Abstract
Mechanisms of innate and adaptive resistance to checkpoint blockade immunotherapy are under intense
investigation with a view to broadening the therapeutic potential of this form of treatment. In a recent manuscript
by Zaretsky and colleagues, mutational events were identified that effectively crippled ongoing immunotherapy
responses in patients treated with anti-PD-1 therapy. These results are discussed in the light of other recent and
ongoing research efforts exploring both mutational and non-mutational resistance mechanisms, highlighting the
critical translational importance of longitudinal tumor sampling.
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Commentary
A commentary on: Zaretsky JM, Garcia-Diaz A, Shin
DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torre-
jon DY, Abril-Rodriguez G, Sandoval S, Barthly L, Saco
J, Homet Moreno B, Mezzadra R, Chmielowski B,
Ruchalski K, Shintaku IP, Sanchez PJ, Puig-Saus C,
Cherry G, Seja E, Kong X, Pang J, Berent-Maoz B,
Comin-Anduix B, Graeber TG, Tumeh PC, Schumacher
TN, Lo RS, Ribas A. “Mutations Associated with
Acquired Resistance to PD-1 Blockade in Melanoma.“-
NEJM 2016;375(9):819–829.
Immunotherapy continues to gain traction as an
effective therapeutic strategy across several cancer types.
Much of the success has been demonstrated through the
use of immune checkpoint blockade targeting cytotoxic
T-lymphocyte associated protein 4 (CTLA-4) and
programmed-death 1 (PD-1)/PD-1 ligand (PD-L1), with
the highest objective response rates observed in cancer
types with a high mutational burden such as melanoma
and non-small cell lung cancer, likely related to an
enriched neoantigen repertoire [1]. However significant
limitations exist with these therapeutic agents when used
as monotherapy, with objective responses to PD-1
blockade observed in only 30–40% of patients [2, 3], and
the majority of patients demonstrating innate resistance.
Acquired resistance to anti-PD-1 therapy is also a prob-
lem, with approximately one quarter of responders later
demonstrating disease progression [4].
Significant efforts are underway to identify mecha-
nisms of innate and acquired resistance to immune
checkpoint inhibitors via translational research in
human samples [5–7], and a recent study published in
the New England Journal of Medicine by Zaretsky and
colleagues described several mutations associated with
acquired resistance to PD-1 blockade in melanoma [8].
In this study, the authors examined 72 patients with
metastatic melanoma treated with PD-1 blockade (Pem-
brolizumab) and observed an initial objective response
rate of 53%. Acquired resistance was observed in 15
patients (35%), as demonstrated by disease progression
after an initial objective response that lasted at least
6 months. Longitudinal tumor biopsies (pre-treatment
and progression) were available in four patients, and
these were deeply queried via whole exome sequencing
of tumor tissue or early passage cell lines and via
immune profiling to gain insight into putative mecha-
nisms of therapeutic resistance.
In these studies, the authors observed broad compar-
ability of the overall mutational load and chromosomal
loss-of-heterozygosity events in the setting of acquired
resistance to anti-PD-1 based therapy, with less than 8%
of non-synonymous mutations unique to progressing
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tumors - even in the setting of new metastatic lesions.
Of note, they identified high-level mutational loss of key
genes involved in immunotherapeutic responses, involv-
ing defects in antigen presentation and in interferon sig-
nalling. In one case, they identified a β2-microglobulin
frameshift deletion leading to HLA class I loss, which
has previously been implicated in immunotherapy resist-
ance [9]. In two cases, JAK mutations were found and
subsequently validated in vitro to confer tumor cell re-
sistance to IFN-γ (JAK2 mutation) or IFN-α/β/γ (JAK1
mutation) despite T cell recognition of tumor antigen.
Importantly, functional loss of JAK2 was associated with
reduced STAT1, STAT3, and IRF1 phosphorylation, as
well as failure to upregulate TAP1, HLA class I, and
PD-L1 expression. This data is highly relevant, and it is
certainly plausible that over longer timeframes in vivo,
such effects could also compromise T cell recognition.
In addition to genomic events, the authors identified
significant alterations in anti-tumor immune responses
in the setting of acquired resistance to anti-PD-1 based
therapy. Namely, the site of immune activity, as defined
by CD8+ T cell infiltrate and/or PD-L1 expression, was
almost exclusively at the tumor invasive margin at re-
lapse. This is important, particularly in light of data from
the same group regarding the importance of assessment
of the distribution of CD8+ T cells within the tumor
microenviroment – demonstrating a higher density of
CD8+ cell infiltrate at the tumoral invasive margin at
baseline and higher intra-tumoral CD8+ T cell infiltrate
early on-treatment in responders to anti-PD-1 based
therapy [10]. Taken together, this suggests that acquired
resistance to anti-PD-1 based therapy is associated with
a reversion of the tumor to a lymphocyte-excluded state.
Though defects in interferon signalling were identified
in this study, the link between this and the apparent T
cell exclusion at time of progression was not defined.
However others have described a critical role for IFN
signalling in the generation of an inflamed tumor micro-
environment and recruitment of leukocytes [11], thus
providing the rationale to suggest that the two may be
tightly related. Recent extension of this work also impli-
cates similar IFN-response compromise caused by JAK1/
2 mutations in cases of intrinsic resistance to PD-1
blockade, however in the studied cohort of melanoma
and mismatch repair deficient colon cancer patients, the
prevalence of such mutations was quite low (1/23 mel-
anoma, 1/16 colon cancer) [12]. Wider surveillance is
required to quantify the broader applicability of such re-
sistance mechanisms to innate and adaptive checkpoint
inhibitor resistance.
The results presented in the manuscript are provoca-
tive, though some limitations clearly exist. Though the
overall study cohort was relatively large, the number of
longitudinal samples available for genomic and immune
analyses was quite limited – thus it is difficult to draw
strong conclusions before these results are validated in
larger cohorts. This problem is not unique to this study,
and highlights a critical need for the global oncology
community to embrace the concept of obtaining tumor
samples at several time points during therapy (ideally at
pre-treatment and progression, with consideration of an
early on-treatment biopsy) to better understand mecha-
nisms of therapeutic resistance [13]. Another limitation
within this study was that one patient’s pre-treatment
biopsy sample was obtained several months before initi-
ating anti-PD-1 therapy, combined with interval treat-
ment with a BRAF inhibitor – thus the observed
genomic events may have been related to selective pres-
sure from prior therapy. Nonetheless, the identification
of mutational resistance events in 3 of 4 evaluable
patients is strikingly reminiscent of the resistance mech-
anisms observed in patients on molecularly targeted
agents, thus warranting very close prospective assess-
ment for the emergence of similar or even cross-reactive
resistance mechanisms in patients treated with com-
bined modalities (ie: combination checkpoint blockade
and BRAF inhibitor-based therapy). It is, however, be-
coming increasingly clear that a significant proportion of
resistance mechanisms may not be related to genomic
events. Functional reprogramming of gene expression is
an increasingly-described resistance mechanism in
targeted therapies [14], and there is emerging data
regarding its impact on immune targets as well [6, 15].
It is also quite clear that a suite of other immunodula-
tory checkpoint molecules such as TIM3, LAG3, and
CTLA4 may act in sequence or in concert to maintain a
continued immunosuppressive state despite adequate
PD-1/PD-L1 blockade [16]. Indeed, recent work from
Benci et al. implicates several alternate T cell inhibitory
receptors and highlights the central role for a persistent
IFN/STAT1-driven network of signalling and epige-
nomic changes underlying PD-1-independent adaptive
resistance to checkpoint blockade [17]. Analysis of larger
cohorts of immunotherapy-treated patients will be
required to determine the impact of such functional
plasticity on adaptive resistance in this context.
This and other studies provide a strong foundation,
though additional questions remain about the broader
efficacy of anti-PD-1 therapy in cancer. Will tumors of
lower mutational load also display prominent tumor
cell-intrinsic mutational resistance mechanisms to
checkpoint inhibitor therapy? To what extent does the
unique microenvironment of distinct metastatic sites in-
fluence mechanisms of resistance? And what is the role
of genomic and immune heterogeneity in driving differ-
ential responses to immune checkpoint blockade? Fur-
ther work will be required to help answer these and
other questions, and will rely heavily on longitudinal
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tumor sampling before and during therapy in larger co-
horts of patients on immune checkpoint blockade,
across cancer types. Combined research platforms
exploring simultaneous molecular and spatial dynamics
will help to delineate the roles played by the diverse
subtypes of tumor-infiltrating leukocytes in the tumor
microenvironment, some of which may have no intrinsic
tumor-specificity or anti-tumor potential. As we move
forward, deep profiling via genomic and immune profil-
ing in longitudinal tumor samples should be strongly
considered in discovery cohorts to help identify putative
predictive biomarkers and mechanisms of resistance,
with targeted profiling of top targets in larger validation
cohorts. Efforts should also be made to perform parallel
analyses in longitudinal “liquid biopsy” samples to iden-
tify circulating genomic and immune predictors of re-
sponse. Finally, incorporation of microbiome sequencing
will also be important given the increased appreciation
of the gut microbiome in shaping anti-tumor immune
responses.
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